EVIANA ANNOUNCES LISTING ON THE CANADIAN SECURITIES EXCHANGE, APPOINTMENT OF DIRECTORS AND OFFICERS, AND SECOND TRANCHE OF FINANCING FOR PROCEEDS OF $1,500,000
NOT FOR DISSEMINATION INTO THE UNITED STATES
TORONTO, ONTARIO – September 11, 2017 – Eviana Health Corporation (the “Company”) is pleased to announce that is has received conditional approval from the Canadian Securities Exchange to list its common shares for trading, and expects to commence trading at market open on Tuesday September 12, 2017 under the stock symbol “EHC”.
The Company also announces that it has appointed additional directors to its board in order to fill vacancies. Dr. Avram Adizes (Chairman), Daniel Bloch, Michael Galloro and Dr. Ljiljana Vujotic have been appointed to the board of directors of the Company effective August 31, 2017. The board of directors of the Company is now therefore comprised of (i) Dr. Avram Adizes, (ii) Sydney Au, (iii) Daniel Bloch, (iv) Michael Galloro, and (v) Dr. Ljiljana Vujotic.
Additionally, the board appointed the Company’s management team, comprised of Dr. Avram Adizes (Chief Executive Officer), Daniel Bloch (President and Secretary), and Sydney Au (Chief Financial Officer). For more information on the directors and officers of the Company, please refer to the biographies below.
The Company is also pleased to announce, further to its press release dated August 22, 2017, that it has closed a second tranche of its non-brokered private placement (the “Offering”) raising an additional $1,500,000 by issuing 1,500,000 units (“Units”), at a price of $1.00 per Unit. Each Unit is comprised of one common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant (“Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share at a price of $1.25 per Common Share until March 11, 2018.
The Company also announces that the board has granted to various directors, officers and consultants of the Company, stock options to acquire an aggregate of 1,250,000 Common Shares, at a price of $1.00 per Common Share until August 31, 2022. In addition, the Company issued an aggregate of 1,000,000 Common Shares to certain consultants of the Company for services provided.
Dr. Avram Adizes – Chief Executive Officer, and Chairman of the Board
Dr. Adizes has over 35 years’ experience in the fields of research and development with international knowledge in creating and implementing top technology solutions. Dr. Adizes previously worked as a Professional Engineer in the 1980s, and was a pioneer in the development of computer science. Dr. Adizes’ has substantial experience in the computer and information technologies marketplace and has the ability to implement new technologies in a wide variety of settings. Dr. Adizes established growth leading projects in fields of public health systems, medical digital image technology for diagnostic purposes, directed development of security infrastructure according to international standards, allowing governments and businesses to communicate electronically with the general public and internally. Dr. Adizes holds a Ph.D. in Computer Science from the joint program at Stanford University and a P.Eng. in electrical engineering from the University of Belgrade.
Sydney Au – Chief Financial Officer, Director
Mr. Au has been active as the Founder, CEO and President of Evitrade Health Systems Corporation, a public digital healthcare technology company, since April 2012 (CSE: EVA) and is also the Founder and Director of a private plastics extrusion manufacturing company, since April 2004. Mr. Au has experience as a director and officer in public companies in a wide range of industries since 2006. He has been active in the day to day operations of both private and public companies in various sectors, and has assisted in developing value for shareholders. He has been involved in restructuring public companies and in various corporate transactions. Mr. Au holds a Bachelor of Arts (Commerce and Economics), a Bachelor of Science (Physical Geography) from the University of Toronto.
Daniel N. Bloch – President, Secretary, and Director
Mr. Bloch has been a member of the Law Society of Upper Canada for 18 years as well as being registered as a Foreign Lawyer with the Israeli Bar Association since 2014. Mr. Bloch’s practice is global in nature and focuses on domestic and international matters in all areas of corporate finance, mergers and acquisitions, joint ventures, private equity and securities law. Mr. Bloch has been practicing law independently since May of 2016, and prior thereto he was a partner of multiple prominent firms. In addition to his international commercial practice, Mr. Bloch regularly represents and provides general corporate and securities law advice to publicly and privately held entities ranging in size from start up to those with established multi-national operations. Mr. Bloch has served as both an officer and director of Canadian and U.S. publicly listed companies. Mr. Bloch holds a Bachelor of Commerce degree from York University and a Bachelor of Laws degree from the University of Victoria.
Michael Galloro – Director
Mr. Galloro is an accomplished financial executive with over 20 years of experience. Mr. Galloro gained public markets experience engaged as a Vice President of Finance for a TSXV listed company operating in the payment processing industry. He then pursued a consulting career focused primarily on the small and mid-cap space working closely with emerging private and publicly listed companies operating globally assisting with financings, M&A, corporate structuring and go public transactions, both in Canada and the US. Michael earned his Chartered Professional Accountant, Chartered Accountant (CPA, CA) designation while working in the financial institutions practice for KPMG LLP and has his Honours Bachelor of Accounting (BAcc) Degree from Brock University.
Dr. Ljiljana Vujotic – Director
Dr. Vujotic has more than 30 years’ experience as a clinician and specialist in the field of neurosurgery, currently as head of the Pediatric Neurosurgery Department, Clinical Center of the Serbia Neurosurgery Division in Belgrade, Serbia, in addition to serving as President of the NT Committee of Quality Improvement of Health Care in Serbia since 2004. Dr. Vujotic was also director (currently deputy) of post-graduate studies and an experienced professor of Neurosurgery at the medical school at the University of Belgrade. Dr. Vujotic holds a medical degree, and MSc. and a Ph.D. from the medical school at the University of Belgrade.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons as defined under applicable securities laws unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
About Eviana Health Corporation
The Company was established for the marketing of proprietary formulations of natural skincare and therapeutic products (cosmeceuticals and nutraceuticals). The Company is now completing the final stages that will enable it to deliver customized consumer skin care products. The Company holds an option to acquire a 100% equity interest in Eviana Inc., an Ontario corporation that holds certain assets in Serbia relating to the cultivation of industrial hemp plant oil for the pharmaceutical, nutraceutical and cosmeceutical industry. Pursuant to this option, the Company has access to a significant grower/supplier of a critical ingredient in topical skin care cream. The Company plans to build on its presence as a cosmeceutical, nutraceutical and pharmaceutical centered business focusing on the market for natural hemp strains of cannabis sativa for bio-chemical cosmeceutical and nutraceutical merchandise and cannabinoid-based topical creams and products.
FOR FURTHER INFORMATION PLEASE CONTACT:
Eviana Health Corporation
Chief Financial Officer
Tel: (604) 780-3311